Skip to main content
Erschienen in: Clinical Research in Cardiology 7/2017

17.02.2017 | Original Paper

Implantable cardioverter/defibrillators for primary prevention in dilated cardiomyopathy post-DANISH: an updated meta-analysis and systematic review of randomized controlled trials

verfasst von: Georg Wolff, Yingfeng Lin, Athanasios Karathanos, Maximilian Brockmeyer, Susanne Wolters, Bernd Nowak, Alexander Fürnkranz, Hisaki Makimoto, Malte Kelm, Volker Schulze

Erschienen in: Clinical Research in Cardiology | Ausgabe 7/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Sudden cardiac death (SCD) is frequent in patients with heart failure due to dilated cardiomyopathy (DCM). Implantable cardioverter/defibrillator (ICD) device therapy is currently used for primary prevention. However, publication of the DANISH trial has recently given reason for doubt, showing no significant improvement in all-cause mortality in comparison to contemporary medical therapy.

Methods

We performed a meta-analysis of all randomized controlled trials comparing ICD therapy to medical therapy (MT) for primary prevention in DCM. The primary outcome was all-cause mortality; secondary analyses were performed on sudden cardiac death, cardiovascular death and non-cardiac death.

Results

Five trials including a total of 2992 patients were included in the pooled analysis. Compared to contemporary medical treatment there was a significant mortality reduction with ICD device therapy [odds ratio (OR) 0.77, 95% confidence interval (CI) 0.64–0.93; p = 0.006]. SCD was decreased significantly (OR 0.43, CI 0.27–0.69; p = 0.0004), while cardiovascular death and non-cardiac death showed no differences. Sensitivity analyses showed no influence of amiodarone therapy on overall results. Analysis of MT details revealed the DANISH population to adhere the most to current guideline recommendations. In addition, it was the only study including a substantial amount of CRT devices (58%).

Conclusions

Our meta-analysis of all available randomized evidence shows a survival benefit of ICD therapy for primary prevention in DCM. DANISH results suggest an attenuation of this ICD advantage when compared to contemporary medical and cardiac resynchronization therapy. Until larger trials have confirmed this finding, ICD therapy should remain the recommendation for primary prevention of SCD in DCM.
Literatur
1.
Zurück zum Zitat Franciosa JA, Wilen M, Ziesche S, Cohn JN (1983) Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy. Am J Cardiol 51:831–836CrossRefPubMed Franciosa JA, Wilen M, Ziesche S, Cohn JN (1983) Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy. Am J Cardiol 51:831–836CrossRefPubMed
3.
Zurück zum Zitat Tamburro P, Wilber D (1992) Sudden death in idiopathic dilated cardiomyopathy. Am Heart J 124:1035–1045CrossRefPubMed Tamburro P, Wilber D (1992) Sudden death in idiopathic dilated cardiomyopathy. Am Heart J 124:1035–1045CrossRefPubMed
4.
Zurück zum Zitat Sweeney MO, Ruskin JN (1994) Mortality benefits and the implantable cardioverter-defibrillator. Circulation 89:1851–1858CrossRefPubMed Sweeney MO, Ruskin JN (1994) Mortality benefits and the implantable cardioverter-defibrillator. Circulation 89:1851–1858CrossRefPubMed
5.
Zurück zum Zitat Uretsky BF, Sheahan RG (1997) Primary prevention of sudden cardiac death in heart failure: will the solution be shocking? J Am Coll Cardiol 30:1589–1597CrossRefPubMed Uretsky BF, Sheahan RG (1997) Primary prevention of sudden cardiac death in heart failure: will the solution be shocking? J Am Coll Cardiol 30:1589–1597CrossRefPubMed
6.
Zurück zum Zitat Moss AJ, Hall WJ, Cannom DS et al (1996) Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter automatic defibrillator implantation trial investigators. N Engl J Med 335:1933–1940CrossRefPubMed Moss AJ, Hall WJ, Cannom DS et al (1996) Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter automatic defibrillator implantation trial investigators. N Engl J Med 335:1933–1940CrossRefPubMed
7.
Zurück zum Zitat Moss AJ, Zareba W, Hall WJ et al (2002) Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346:877–883CrossRefPubMed Moss AJ, Zareba W, Hall WJ et al (2002) Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346:877–883CrossRefPubMed
8.
Zurück zum Zitat Bänsch D, Antz M, Boczor S et al (2002) Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the cardiomyopathy trial (CAT). Circulation 105:1453–1458CrossRefPubMed Bänsch D, Antz M, Boczor S et al (2002) Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the cardiomyopathy trial (CAT). Circulation 105:1453–1458CrossRefPubMed
9.
Zurück zum Zitat Kuck KH, Cappato R, Siebels J, Rüppel R (2000) Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the cardiac arrest study hamburg (CASH). Circulation 102:748–754CrossRefPubMed Kuck KH, Cappato R, Siebels J, Rüppel R (2000) Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the cardiac arrest study hamburg (CASH). Circulation 102:748–754CrossRefPubMed
10.
Zurück zum Zitat Connolly SJ, Gent M, Roberts RS et al (2000) Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 101:1297–1302CrossRefPubMed Connolly SJ, Gent M, Roberts RS et al (2000) Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 101:1297–1302CrossRefPubMed
11.
Zurück zum Zitat Connolly SJ, Hallstrom AP, Cappato R et al (2000) Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs implantable defibrillator study. Cardiac arrest study hamburg. Canadian implantable defibrillator study. Eur Heart J 21:2071–2078CrossRefPubMed Connolly SJ, Hallstrom AP, Cappato R et al (2000) Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs implantable defibrillator study. Cardiac arrest study hamburg. Canadian implantable defibrillator study. Eur Heart J 21:2071–2078CrossRefPubMed
12.
Zurück zum Zitat The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators (1997) A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The antiarrhythmics versus implantable defibrillators (AVID) investigators. N Engl J Med 337:1576–1583 The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators (1997) A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The antiarrhythmics versus implantable defibrillators (AVID) investigators. N Engl J Med 337:1576–1583
13.
Zurück zum Zitat Ponikowski P, Voors AA, Anker SD et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 37:2129–2200CrossRefPubMed Ponikowski P, Voors AA, Anker SD et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 37:2129–2200CrossRefPubMed
14.
Zurück zum Zitat Priori SG, Members AF, Blomström-Lundqvist C et al (2015) 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 36(41):2757–2759CrossRefPubMed Priori SG, Members AF, Blomström-Lundqvist C et al (2015) 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 36(41):2757–2759CrossRefPubMed
15.
Zurück zum Zitat Yancy CW, Jessup M, Bozkurt B et al (2013) 2013 ACCF/AHA guideline for the management of heart failure a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation 128:e240–e327CrossRefPubMed Yancy CW, Jessup M, Bozkurt B et al (2013) 2013 ACCF/AHA guideline for the management of heart failure a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation 128:e240–e327CrossRefPubMed
16.
Zurück zum Zitat Theuns DAMJ, Smith T, Hunink MGM et al (2010) Effectiveness of prophylactic implantation of cardioverter-defibrillators without cardiac resynchronization therapy in patients with ischaemic or non-ischaemic heart disease: a systematic review and meta-analysis. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Europace 12(11):1564–1570CrossRef Theuns DAMJ, Smith T, Hunink MGM et al (2010) Effectiveness of prophylactic implantation of cardioverter-defibrillators without cardiac resynchronization therapy in patients with ischaemic or non-ischaemic heart disease: a systematic review and meta-analysis. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Europace 12(11):1564–1570CrossRef
17.
Zurück zum Zitat Streitner F, Kuschyk J, Dietrich C et al (2011) Comparison of ventricular tachyarrhythmia characteristics in patients with idiopathic dilated or ischemic cardiomyopathy and defibrillators implanted for primary prevention. Clin Cardiol 34:604–609CrossRefPubMed Streitner F, Kuschyk J, Dietrich C et al (2011) Comparison of ventricular tachyarrhythmia characteristics in patients with idiopathic dilated or ischemic cardiomyopathy and defibrillators implanted for primary prevention. Clin Cardiol 34:604–609CrossRefPubMed
18.
Zurück zum Zitat Liu X, Yu H, Pei J et al (2014) Clinical characteristics and long-term prognosis in patients with chronic heart failure and reduced ejection fraction in China. Heart Lung Circ 23:818–826CrossRefPubMed Liu X, Yu H, Pei J et al (2014) Clinical characteristics and long-term prognosis in patients with chronic heart failure and reduced ejection fraction in China. Heart Lung Circ 23:818–826CrossRefPubMed
19.
Zurück zum Zitat Bardy GH, Lee KL, Mark DB et al (2005) Amiodarone or an Implantable cardioverter–defibrillator for congestive heart failure. N Engl J Med 352:225–237CrossRefPubMed Bardy GH, Lee KL, Mark DB et al (2005) Amiodarone or an Implantable cardioverter–defibrillator for congestive heart failure. N Engl J Med 352:225–237CrossRefPubMed
20.
Zurück zum Zitat Desai AS, Fang JC, Maisel WH, Baughman KL (2004) Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA 292:2874–2879CrossRefPubMed Desai AS, Fang JC, Maisel WH, Baughman KL (2004) Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA 292:2874–2879CrossRefPubMed
21.
Zurück zum Zitat Køber L, Thune JJ, Nielsen JC et al (2016) Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med 375:1221–1230CrossRefPubMed Køber L, Thune JJ, Nielsen JC et al (2016) Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med 375:1221–1230CrossRefPubMed
23.
Zurück zum Zitat Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700CrossRefPubMedPubMedCentral Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188CrossRefPubMed DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188CrossRefPubMed
26.
Zurück zum Zitat Strickberger SA, Hummel JD, Bartlett TG et al (2003) Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia–AMIOVIRT. J Am Coll Cardiol 41:1707–1712CrossRefPubMed Strickberger SA, Hummel JD, Bartlett TG et al (2003) Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia–AMIOVIRT. J Am Coll Cardiol 41:1707–1712CrossRefPubMed
27.
Zurück zum Zitat Kadish A, Dyer A, Daubert JP et al (2004) Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 350:2151–2158CrossRefPubMed Kadish A, Dyer A, Daubert JP et al (2004) Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 350:2151–2158CrossRefPubMed
28.
Zurück zum Zitat CIBIS-II Investigators and Committees (1999) The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet Lond Engl 353:9–13 CIBIS-II Investigators and Committees (1999) The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet Lond Engl 353:9–13
29.
Zurück zum Zitat MERIT-HF Study Group (1999) Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet Lond Engl 353:2001–2007. MERIT-HF Study Group (1999) Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet Lond Engl 353:2001–2007.
30.
Zurück zum Zitat Investigators* TS (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325:293–302CrossRef Investigators* TS (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325:293–302CrossRef
31.
Zurück zum Zitat Sharpe DN, Murphy J, Coxon R, Hannan SF (1984) Enalapril in patients with chronic heart failure: a placebo-controlled, randomized, double-blind study. Circulation 70:271–278CrossRefPubMed Sharpe DN, Murphy J, Coxon R, Hannan SF (1984) Enalapril in patients with chronic heart failure: a placebo-controlled, randomized, double-blind study. Circulation 70:271–278CrossRefPubMed
32.
Zurück zum Zitat Pitt B, Zannad F, Remme WJ et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341:709–717CrossRefPubMed Pitt B, Zannad F, Remme WJ et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341:709–717CrossRefPubMed
33.
Zurück zum Zitat Zannad F, McMurray JJV, Krum H et al (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364:11–21CrossRefPubMed Zannad F, McMurray JJV, Krum H et al (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364:11–21CrossRefPubMed
34.
Zurück zum Zitat McMurray JJV, Packer M, Desai AS et al (2014) Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993–1004CrossRefPubMed McMurray JJV, Packer M, Desai AS et al (2014) Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993–1004CrossRefPubMed
35.
Zurück zum Zitat Swedberg K, Komajda M, Böhm M et al (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. The Lancet 376:875–885CrossRef Swedberg K, Komajda M, Böhm M et al (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. The Lancet 376:875–885CrossRef
36.
Zurück zum Zitat Swedberg K, Komajda M, Böhm M et al (2012) Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. J Am Coll Cardiol 59:1938–1945CrossRefPubMed Swedberg K, Komajda M, Böhm M et al (2012) Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. J Am Coll Cardiol 59:1938–1945CrossRefPubMed
37.
Zurück zum Zitat Cleland JGF, Daubert J-C, Erdmann E et al (2005) The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352:1539–1549CrossRefPubMed Cleland JGF, Daubert J-C, Erdmann E et al (2005) The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352:1539–1549CrossRefPubMed
38.
Zurück zum Zitat Bristow MR, Saxon LA, Boehmer J et al (2004) Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350:2140–2150CrossRefPubMed Bristow MR, Saxon LA, Boehmer J et al (2004) Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350:2140–2150CrossRefPubMed
39.
Zurück zum Zitat Rivero-Ayerza M, Theuns DAMJ, Garcia-Garcia HM et al (2006) Effects of cardiac resynchronization therapy on overall mortality and mode of death: a meta-analysis of randomized controlled trials. Eur Heart J 27:2682–2688CrossRefPubMed Rivero-Ayerza M, Theuns DAMJ, Garcia-Garcia HM et al (2006) Effects of cardiac resynchronization therapy on overall mortality and mode of death: a meta-analysis of randomized controlled trials. Eur Heart J 27:2682–2688CrossRefPubMed
40.
Zurück zum Zitat Cleland JG, Abraham WT, Linde C et al (2013) An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J 34:3547–3556CrossRefPubMedPubMedCentral Cleland JG, Abraham WT, Linde C et al (2013) An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J 34:3547–3556CrossRefPubMedPubMedCentral
41.
Zurück zum Zitat Finegold JA, Raphael CE, Levy WC et al (2013) Quantification of survival gain from cardiac resynchronization therapynonlinear growth with time, and greater gain in low-risk patients, make raw trial data an underestimate of real-world behavior. J Am Coll Cardiol 62:2406–2413CrossRefPubMedPubMedCentral Finegold JA, Raphael CE, Levy WC et al (2013) Quantification of survival gain from cardiac resynchronization therapynonlinear growth with time, and greater gain in low-risk patients, make raw trial data an underestimate of real-world behavior. J Am Coll Cardiol 62:2406–2413CrossRefPubMedPubMedCentral
42.
Zurück zum Zitat Abraham WT, Young JB, Wheelan K et al (2008) Comparison of sudden cardiac death in heart failure patients with cardiac resynchronization and defibrillator therapy (CRT-D) versus CRT alone (CRT-P). J Card Fail 14:S71CrossRef Abraham WT, Young JB, Wheelan K et al (2008) Comparison of sudden cardiac death in heart failure patients with cardiac resynchronization and defibrillator therapy (CRT-D) versus CRT alone (CRT-P). J Card Fail 14:S71CrossRef
43.
Zurück zum Zitat Moss AJ, Hall WJ, Cannom DS et al (2009) Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 361:1329–1338CrossRefPubMed Moss AJ, Hall WJ, Cannom DS et al (2009) Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 361:1329–1338CrossRefPubMed
44.
Zurück zum Zitat Goldenberg I, Vyas AK, Hall WJ et al (2008) Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol 51:288–296CrossRefPubMed Goldenberg I, Vyas AK, Hall WJ et al (2008) Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol 51:288–296CrossRefPubMed
45.
Zurück zum Zitat Rubin GA (2016) Primary prevention implantable cardioverter defibrillator placement in the elderly. In: Am Coll Cardiol. http%3a%2f%2fwww.acc.org%2flatest-in-cardiology%2farticles%2f2016%2f05%2f24%2f07%2f53%2fprimary-prevention-implantable-cardioverter-defibrillator-placement-in-the-elderly. Accessed 13 Sep 2016 Rubin GA (2016) Primary prevention implantable cardioverter defibrillator placement in the elderly. In: Am Coll Cardiol. http%3a%2f%2fwww.acc.org%2flatest-in-cardiology%2farticles%2f2016%2f05%2f24%2f07%2f53%2fprimary-prevention-implantable-cardioverter-defibrillator-placement-in-the-elderly. Accessed 13 Sep 2016
46.
Zurück zum Zitat Zeitler EP, Hellkamp AS, Fonarow GC et al (2015) Primary prevention implantable cardioverter-defibrillators and survival in older women. JACC Heart Fail 3:159–167CrossRefPubMed Zeitler EP, Hellkamp AS, Fonarow GC et al (2015) Primary prevention implantable cardioverter-defibrillators and survival in older women. JACC Heart Fail 3:159–167CrossRefPubMed
47.
Zurück zum Zitat Zwanziger J, Hall WJ, Dick AW et al (2006) The cost effectiveness of implantable cardioverter-defibrillators: results from the multicenter automatic defibrillator implantation trial (MADIT)-II. J Am Coll Cardiol 47:2310–2318CrossRefPubMed Zwanziger J, Hall WJ, Dick AW et al (2006) The cost effectiveness of implantable cardioverter-defibrillators: results from the multicenter automatic defibrillator implantation trial (MADIT)-II. J Am Coll Cardiol 47:2310–2318CrossRefPubMed
48.
Zurück zum Zitat Medical Advisory Secretariat (2005) Implantable cardioverter defibrillators. Prophylactic use: an evidence-based analysis. Ont Health Technol Assess Ser 5:1–74 Medical Advisory Secretariat (2005) Implantable cardioverter defibrillators. Prophylactic use: an evidence-based analysis. Ont Health Technol Assess Ser 5:1–74
Metadaten
Titel
Implantable cardioverter/defibrillators for primary prevention in dilated cardiomyopathy post-DANISH: an updated meta-analysis and systematic review of randomized controlled trials
verfasst von
Georg Wolff
Yingfeng Lin
Athanasios Karathanos
Maximilian Brockmeyer
Susanne Wolters
Bernd Nowak
Alexander Fürnkranz
Hisaki Makimoto
Malte Kelm
Volker Schulze
Publikationsdatum
17.02.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Clinical Research in Cardiology / Ausgabe 7/2017
Print ISSN: 1861-0684
Elektronische ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-017-1079-0

Weitere Artikel der Ausgabe 7/2017

Clinical Research in Cardiology 7/2017 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.